The role of Bryostatin and PMA (Phorbole Myristate Acetate) in enhancing ZFN’s Anti-HIV effects

Abstract

Purpose: Investigate the efficacy of protein kinase activators in enhancing the activity of ZFN and maintain the average of CD4/CD8 in the treatment of AIDS by using protein kinase activators like bryostatin and PMA. Materials and methods: Balb/C mice were infected with hiv-1ADA (tCID50 102×5 per mouse), A week later, ZFN was then injected with a concentration of 3,100ng, PMA with a dose 100ng per animal and Bryostatin 40 μg/kg, intraperitoneally. And Antiviral treatment was continued for seven weeks, using oral tenofovir at a dose of 4.5mg, emtricitabine at a dose of 3mg, and efavirenz at a dose of 18mg, daily At the end of the study, blood samples were withdrawn from the retro-orbital mouse eye and CD4/CD8 was measured by flow cytometry. Results: The pathophysiological changes decreased in the group treated with ZFN compared to the control infected group with significant differences, but there are no significant differences between and the groups treated with ZFN+Bry (HIV+ Z +B), ZFN +PMA (HIV+ Z +PMA) and ART group with CD4/CD8 ratio in these compared to the infected irradiated control group (HIV). Conclusion: Bryostatin and PMA cannot enhance the effect of ZFN in treating HIV infection.